{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:09:41Z","timestamp":1764493781527},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Rituximab plus CHOP (R-CHOP) significantly improved the outcome of diffuse large B cell lymphoma (DLBCL), a common sub-type of non-Hodgkin lymphoma. But 40% \u2013 50% of DLBCL patients cannot be cured by this regimen. Some clinical trials showed that bevacizumab might be useful in the treatment of DLBCL. This study evaluated the safety and efficacy of bevacizumab combined with the R-CHOP (A-R-CHOP) regimen in Chinese patients with previously untreated DLBCL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with previously untreated DLBCL received A-R-CHOP regimen therapy. All patients with complete response (CR)\/ unconfirmed complete response(CRu) after 8 cycles of A-R-CHOP received the bevacizumab maintenance therapy once every 3 weeks. The remained bulky disease was treated with radiotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Seven Chinese patients were treated. All of them had bulky diseases. One patient had progressive disease after 4 cycles of A-R-CHOP therapy. The rest six patients completed 8 cycles of A-R-CHOP treatment. All of these six patients reached CR\/CRu (5 CR, 1 CRu). Bevacizumab maintenance therapy was given to 4 CR patients. All 7 patients experienced Grade 3\/4 hematologic adverse events; additionally, one had Grade 3 gastrointestinal toxicity and one had Grade 1 epistaxis. During bevacizumab maintenance therapy, one patient had Grade 1 gingival bleeding, another experienced Grade 1 proteinuria and then Grade 3 congestive heart failure 4 months after completion of maintenance therapy. At the end of July 2013, the patient who had progressive disease after 4 cycles of A-R-CHOP died of progressive disease, the other six remained CR response.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The A-R-CHOP regimen is effective for untreated DLBCL, but may cause bevacizumab-specific toxicities, which should be monitored.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1475-2867-14-5","type":"journal-article","created":{"date-parts":[[2014,1,18]],"date-time":"2014-01-18T18:05:13Z","timestamp":1390068313000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Safety and efficacy of bevacizumab combined with R-CHOP regimen in seven Chinese patients with untreated diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"14","author":[{"given":"Zhiying","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhitao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ningjing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meifeng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingyan","family":"Ping","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Ding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqin","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,18]]},"reference":[{"key":"499_CR1","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/ijc.25516","volume":"127","author":"J Ferlay","year":"2010","unstructured":"Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008. Int J Cancer. 2010, 127: 2293-2917.","journal-title":"Int J Cancer"},{"key":"499_CR2","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/annonc\/mdq203","volume":"21","author":"H Tilly","year":"2010","unstructured":"Tilly H, Drey LM, ESMO Guidelines Working Group: Diffuse large B-cell non-Hodgkin\u2019s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010, 21: 172-174. 10.1093\/annonc\/mdq203.","journal-title":"Ann Oncol"},{"issue":"2","key":"499_CR3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA: Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013, 87 (2): 146-171. 10.1016\/j.critrevonc.2012.12.009.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"12","key":"499_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Ferm\u00e9 C, Tilly H: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood. 2010, 116 (12): 2040-2045. 10.1182\/blood-2010-03-276246.","journal-title":"Blood"},{"key":"499_CR5","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Tr\u00fcmper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M, German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL): Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008, 9: 105-116. 10.1016\/S1470-2045(08)70002-0.","journal-title":"Lancet Oncol"},{"key":"499_CR6","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"2","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, Shepherd L, Gill DS, Walewski J, Pettengell R, Jaeger U, Zinzani PL, Shpilberg O, Kvaloy S, de Nully Brown P, Stahel R, Milpied N, L\u00f3pez-Guillermo A, Poeschel V, Grass S, Loeffler M, Murawski N, MabThera InternationalTrial (MInT) Group: CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial Group. Lancet Oncol. 2011, 2: 1013-1022.","journal-title":"Lancet Oncol"},{"key":"499_CR7","first-page":"2899","volume":"22","author":"A Potti","year":"2002","unstructured":"Potti A, Ganti AK, Kargas S, Koch M: Immunohistochemical detection of C-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in mantle cell lymphoma. Anticancer Res. 2002, 22: 2899-2901.","journal-title":"Anticancer Res"},{"issue":"4","key":"499_CR8","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1038\/bcj.2012.12","volume":"2","author":"F Mori","year":"2012","unstructured":"Mori F, Ishida T, Ito A, Sato F, Masaki A, Takino H, Ri M, Kusumoto S, Komatsu H, Ueda R, Inagaki H, Iida S: Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. Blood Cancer J. 2012, 2 (4): e67-10.1038\/bcj.2012.12.","journal-title":"Blood Cancer J"},{"key":"499_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1093\/annonc\/mdn666","volume":"20","author":"J Ruan","year":"2009","unstructured":"Ruan J, Hajjar K, Rafii S, Leonard JP: Angiogenesis and antiangiogenic therapy in non-Hodgkin\u2019s lymphoma. Ann Oncol. 2009, 20: 413-424.","journal-title":"Ann Oncol"},{"issue":"16S","key":"499_CR10","doi-asserted-by":"crossref","first-page":"6592","DOI":"10.1200\/jco.2005.23.16_suppl.6592","volume":"23","author":"AT Stopeck","year":"2005","unstructured":"Stopeck AT, Bellamy W, Unger J, Rimsza L, Iannone M, Fisher RI, Miller TP: Phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin\u2019s lymphoma (NHL): Southwest Oncology Group Study S0108. J Clin Oncol. 2005, 23 (16S): 6592-","journal-title":"J Clin Oncol"},{"key":"499_CR11","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1080\/10428190902856808","volume":"50","author":"AT Stopeck","year":"2009","unstructured":"Stopeck AT, Unger JM, Rimsza LM, Bellamy WT, Iannone M, Persky DO, Leblanc M, Fisher RI, Miller TP: A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest Oncology Group Study S0108. Leuk Lymphoma. 2009, 50: 728-735. 10.1080\/10428190902856808.","journal-title":"Leuk Lymphoma"},{"key":"499_CR12","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1080\/10428190600563821","volume":"47","author":"KN Ganjoo","year":"2006","unstructured":"Ganjoo KN, An CS, Robertson MJ, Gordon LI, Sen JA, Weisenbach J, Li S, Weller EA, Orazi A, Horning SJ: Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B cell lymphoma: Safety, biomarker and pharmacokinetic analysis. Leuk Lymphoma. 2006, 47: 998-1005. 10.1080\/10428190600563821.","journal-title":"Leuk Lymphoma"},{"key":"499_CR13","unstructured":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. International Agency for Research on Cancer. Edited by: Swerdlow S, Campo E, Harris NL. 2008, Geneva, Switzerland: World Health Organization"},{"key":"499_CR14","first-page":"2351","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-L\u00f3pez A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP: Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol. 1999, 17: 2351-2352.","journal-title":"J Clin Oncol"},{"key":"499_CR15","unstructured":"Common Terminology Criteria for Adverse Events v3.0 (CTCAE). 2006, : , http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf Accessed July 30, 2013"},{"issue":"12","key":"499_CR16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1634\/theoncologist.2009-0155","volume":"15","author":"S Geiger-Gritsch","year":"2010","unstructured":"Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U: Safety of bevacizumab in patients with advanced cancer:a meta-analysis of randomized controlled trial. Oncologist. 2010, 15 (12): 1179-1191.","journal-title":"Oncologist"},{"key":"499_CR17","unstructured":"Ganjoo K, Hong F, Horning SJ, Gascoyne RD, Natkunam Y, Swinnen LJ, Habermann TM, Kahl BS, Advani RH: Bevacizumab and CHOP (a-CHOP) in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative group study (E2404). Leuk Lymphoma. in press"},{"key":"499_CR18","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1182\/blood-2012-04-423079","volume":"120","author":"AT Stopeck","year":"2012","unstructured":"Stopeck AT, Unger JM, Rimsza LM, LeBlanc M, Farnsworth B, Iannone M, Glenn MJ, Fisher RI, Miller TP: A phase 2 trial of standard-dose cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) and rituximab plus bevacizumab for patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: SWOG 0515. Blood. 2012, 120: 1210-1217. 10.1182\/blood-2012-04-423079.","journal-title":"Blood"},{"key":"499_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000314980","volume":"79","author":"S Hapani","year":"2010","unstructured":"Hapani S, Sher A, Chu D, Wu S: Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. Oncology. 2010, 79: 27-38. 10.1159\/000314980.","journal-title":"Oncology"},{"key":"499_CR20","first-page":"9","volume":"6","author":"D Miles","year":"2008","unstructured":"Miles D: Management of toxicity in patients receiving therapy with bevacizumab. EJC. 2008, 6: 9-39.","journal-title":"EJC"},{"key":"499_CR21","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1681\/ASN.2010020167","volume":"21","author":"S Wu","year":"2010","unstructured":"Wu S, Kim C, Baer L, Zhu X: Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010, 21: 1381-1389. 10.1681\/ASN.2010020167.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"499_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","volume":"358","author":"V Eremina","year":"2008","unstructured":"Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, Richardson C, Kopp JB, Kabir MG, Backx PH, Gerber HP, Ferrara N, Barisoni L, Alpers CE, Quaggin SE: VEGF inhibition and renal thrombotic microangiopathy. N Eng J Med. 2008, 358 (11): 1129-1136. 10.1056\/NEJMoa0707330.","journal-title":"N Eng J Med"},{"issue":"1","key":"499_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1161\/CIRCRESAHA.109.206920","volume":"106","author":"H Cheng","year":"2010","unstructured":"Cheng H, Force T: Molecular mechanisms of cardiovascular toxicity of targeted cancer therapeutics. Circ Res. 2010, 106 (1): 21-34. 10.1161\/CIRCRESAHA.109.206920.","journal-title":"Circ Res"},{"issue":"12","key":"499_CR24","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007, 96 (12): 1788-1795. 10.1038\/sj.bjc.6603813.","journal-title":"Br J Cancer"},{"key":"499_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1634\/theoncologist.2009-0252","volume":"15","author":"C Vaklavas","year":"2010","unstructured":"Vaklavas C, Lenihan D, Kurarock R, Tsimberidou AM: Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?. Oncologist. 2010, 15: 130-141. 10.1634\/theoncologist.2009-0252.","journal-title":"Oncologist"},{"key":"499_CR26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1200\/JCO.2011.35.5008","volume":"29","author":"EA Hawkes","year":"2011","unstructured":"Hawkes EA, Okines AF, Plummer C, Cunningham D: Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol. 2011, 29: 560-562. 10.1200\/JCO.2011.35.5008.","journal-title":"J Clin Oncol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1475-2867-14-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T02:51:04Z","timestamp":1630551064000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/1475-2867-14-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,18]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["499"],"URL":"https:\/\/doi.org\/10.1186\/1475-2867-14-5","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,18]]},"assertion":[{"value":"26 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"5"}}